tiprankstipranks
Trending News
More News >

Avacta Reports Promising Results in Salivary Gland Cancer Trial

Story Highlights
  • Avacta announced a partial response in a salivary gland cancer patient during its Phase 1b trial.
  • The development highlights the high unmet need for effective treatments in this rare cancer type.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Avacta Reports Promising Results in Salivary Gland Cancer Trial

Don’t Miss TipRanks’ Half-Year Sale

Avacta Group plc ( (GB:AVCT) ) has shared an announcement.

Avacta Group plc announced a promising partial response in a patient with metastatic salivary gland cancer during the dose expansion phase of its FAP-Dox (AVA6000) Phase 1b trial. This development is significant given the high unmet need for effective treatments in this rare cancer type, which lacks a preferred standard therapy. The company plans to release final data from the AVA6000 Phase 1a trial later in 2025 and will provide a business update at its upcoming Annual General Meeting.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £40.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

More about Avacta Group plc

Avacta Therapeutics is a clinical-stage life sciences company focused on developing highly potent cancer therapies using its proprietary pre|CISION® platform. This platform is designed to deliver targeted oncology drugs by concentrating potent warheads in the tumor microenvironment while sparing normal tissues. Avacta’s pipeline includes pre|CISION® peptide drug conjugates and Affimer® drug conjugates, offering unique advantages over traditional antibody drug conjugates.

Average Trading Volume: 1,740,301

Technical Sentiment Signal: Sell

Current Market Cap: £116M

See more insights into AVCT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1